NASDAQ:LPTX - Leap Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.88
  • Forecasted Upside: 193.67 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.04 (-2.35%)

This chart shows the closing price for LPTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Leap Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LPTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LPTX

Analyst Price Target is $4.88
▲ +193.67% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Leap Therapeutics in the last 3 months. The average price target is $4.88, with a high forecast of $8.00 and a low forecast of $3.50. The average price target represents a 193.67% upside from the last price of $1.66.

This chart shows the closing price for LPTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Leap Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2021Piper SandlerLower Price TargetOverweight$6.00 ➝ $4.00Low
3/23/2021Raymond JamesSet Price TargetOutperform$3.50Medium
3/15/2021Raymond JamesSet Price TargetOutperform$3.50High
3/2/2021Raymond JamesBoost Price TargetOutperform$2.50 ➝ $3.50High
12/23/2020Raymond JamesSet Price TargetOutperform$2.50N/A
11/16/2020Raymond JamesSet Price TargetOutperform$2.50Low
11/10/2020Raymond JamesSet Price TargetOutperform$2.50Low
9/22/2020Raymond JamesSet Price TargetOutperform$2.50Low
8/17/2020Raymond JamesSet Price TargetOutperform$2.50Medium
8/17/2020HC WainwrightLower Price TargetBuy$5.00 ➝ $4.00High
7/19/2020LADENBURG THALM/SH SHReiterated RatingMarket Perform ➝ Buy$8.00High
6/29/2020Piper SandlerInitiated CoverageOverweight$6.00High
6/12/2020Raymond JamesSet Price TargetOutperform$2.50High
5/19/2020HC WainwrightReiterated RatingBuy$2.50 ➝ $5.00Medium
5/17/2020Raymond JamesSet Price TargetOutperform$2.50Medium
4/24/2020Raymond JamesSet Price TargetOutperform$2.50Low
3/17/2020Raymond JamesSet Price TargetOutperform$2.50Low
3/17/2020HC WainwrightLower Price TargetBuy$3.25 ➝ $2.50High
2/10/2020Robert W. BairdInitiated CoverageOutperform$6.00High
1/8/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$2.50Low
11/15/2019HC WainwrightReiterated RatingBuy$3.25High
11/15/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
9/19/2019Raymond JamesSet Price TargetOutperform$5.00Low
9/13/2019Raymond JamesInitiated CoverageOutperform$5.00Medium
12/19/2018Raymond JamesLower Price TargetOutperform ➝ Outperform$13.00 ➝ $8.00Medium
11/13/2018HC WainwrightSet Price TargetBuy$13.00Low
10/23/2018HC WainwrightSet Price TargetBuy$13.00Medium
4/12/2018HC WainwrightInitiated CoverageBuy$12.50Low
3/7/2017LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$18.00N/A
3/1/2017CitigroupInitiated CoverageMarket PerformN/A
2/28/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$13.00N/A
(Data available from 6/22/2016 forward)
Leap Therapeutics logo
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.66
Low: $1.63
High: $1.68

50 Day Range

MA: $1.66
Low: $1.48
High: $1.82

52 Week Range

Now: $1.66
Low: $1.43
High: $3.24


207,871 shs

Average Volume

663,680 shs

Market Capitalization

$99.06 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Leap Therapeutics?

The following Wall Street analysts have issued stock ratings on Leap Therapeutics in the last twelve months: HC Wainwright, LADENBURG THALM/SH SH, Piper Sandler, Raymond James, and Zacks Investment Research.
View the latest analyst ratings for LPTX.

What is the current price target for Leap Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Leap Therapeutics in the last year. Their average twelve-month price target is $4.88, suggesting a possible upside of 186.8%. LADENBURG THALM/SH SH has the highest price target set, predicting LPTX will reach $8.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $3.50 for Leap Therapeutics in the next year.
View the latest price targets for LPTX.

What is the current consensus analyst rating for Leap Therapeutics?

Leap Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LPTX will outperform the market and that investors should add to their positions of Leap Therapeutics.
View the latest ratings for LPTX.

What other companies compete with Leap Therapeutics?

How do I contact Leap Therapeutics' investor relations team?

Leap Therapeutics' physical mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company's listed phone number is 617-714-0360 and its investor relations email address is [email protected] The official website for Leap Therapeutics is